Want to see GRDN full AI Analyst Report?
EarningsQ2 2026 Earnings Report
GRDN Q2 2026 EPS Results
Actual EPS$0.29
Consensus EPS$0.26
Beat/MissBeat by +$0.03
One Year Ago EPS$0.23
GRDN Q2 2026 Revenue Results
Actual Revenue$351.77M
Expected Revenue$340.45M
Beat/MissBeat by +$11.32M
YoY Revenue Growth+2.16%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
GRDN Upcoming Earnings
Guardian Pharmacy Services, Inc. Class A's next earnings date is estimated for November 17, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
GRDN Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call reflected a positive operational and financial trajectory: strong adjusted EBITDA growth (23% YTD; 19% Q/Q), improved gross profit (+18% YoY), raised full-year guidance, robust clinical impact and disciplined capital allocation with nearly $90M cash and active M&A/greenfield expansion. Offsetting these positives are clear reimbursement headwinds from IRA pricing reductions that materially depressed reported revenue (Q2 +2%) and are expected to cause low single-digit reported declines in H2, continued margin dilution from ramping acquisitions/greenfields (though improving), and some cost pressures (fuel). Management emphasized mitigation actions, internal succession and disciplined deployment of capital, leaving the outlook upgraded but with ongoing uncertainty tied to future IRA tranches and integration ramps.Company Guidance
Raised Full-Year Guidance
Company raised 2026 revenue guidance to $1.43B–$1.45B (from $1.40B–$1.42B) and adjusted EBITDA to $129M–$131M (from $123M–$127M), reflecting confidence based on year-to-date performance.
Strong Adjusted EBITDA Growth
Adjusted EBITDA grew 23% in the first half of 2026 vs. the first half of 2025; quarterly adjusted EBITDA was $29.7M, up 19% year-over-year, with an adjusted EBITDA margin of 8.4%.
Underlying Revenue Momentum (Pre-IRA Impact)
Reported revenue grew 2% in Q2 2026 to $351.2M, but management stated that absent IRA-related pricing reductions revenue would have increased low double-digits in the quarter and first half — indicating stronger underlying organic growth.
Gross Profit and Margin Improvement
Gross profit increased to $80.0M in the quarter, up 18% year-over-year, with gross margin of 22.8% despite pressure from higher fuel costs.
Operational Scale and Clinical Impact
Through H1 2026 clinicians served over 300,000 residents; pharmacy teams completed >50,000 clinical interventions affecting >45,000 residents, identifying ~4,000 allergy risks and ~5,000 potential duplicate therapies; early falls-risk program data shows meaningful outcome improvements.
Cash Position and Balance Sheet Strength
Ended Q2 with nearly $90M in cash (up from ~$65M in prior quarter); management highlighted normalized cash conversion following a one-time working capital reset and emphasized financial flexibility for M&A and greenfield investments.
Progress on M&A and Organic Expansion
Completed acquisition of Wellness Concepts (Shenandoah Valley, VA) and launched a new greenfield pharmacy in Lexington, KY; management expects smaller 2026 acquisitions to contribute modestly and larger prior-year acquisitions to be fully lapped.
Leadership and Organizational Strength
Promotions appointed David Morris to COO and Will Mudd to CFO, reflecting internal succession; implemented new regional leadership structure (8 regional SVPs) to drive consistency, accountability and local support across operations.
GRDN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed